Ken Griffin Rani Therapeutics Holdings, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Rani Therapeutics Holdings, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 14,000 shares of RANI stock, worth $7,420. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,000
Previous 21,300
34.27%
Holding current value
$7,420
Previous $26,000
73.08%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding RANI
# of Institutions
45Shares Held
6.32MCall Options Held
29.4KPut Options Held
0-
Armistice Capital, LLC New York, NY3.15MShares$1.67 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA800KShares$423,8290.0% of portfolio
-
Nan Fung Group Holdings LTD Central, K3494KShares$261,5990.48% of portfolio
-
United Services Automobile Association San Antonio, TX303KShares$160,4530.02% of portfolio
-
Geode Capital Management, LLC Boston, MA191KShares$100,9950.0% of portfolio
About Rani Therapeutics Holdings, Inc.
- Ticker RANI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,492,000
- Market Cap $13M
- Description
- Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed P...